Journal
LUPUS
Volume 17, Issue 5, Pages 405-411Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203308090025
Keywords
-
Categories
Funding
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049772, R01AR038889] Funding Source: NIH RePORTER
- NIAMS NIH HHS [R01 AR038889-16, R01 AR049772, R01 AR038889] Funding Source: Medline
Ask authors/readers for more resources
The antiphospholipid antibody syndrome (APS) is characterized by recurrent arterial and venous thrombosis and/or pregnancy in association with antiphospholipid (aPL) antibodies. The pathogenic mechanisms in APS that lead to in vivo injury are incompletely understood. Recent evidence suggests that APL antibodies alter regulation of haemostasis and induce activation of complement. We will discuss the current knowledge on how aPL antibodies trigger increased inflammation and enhanced thrombotic tendency, and thereby lead to tissue damage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available